Normalization of Platelet Count after Romiplostim Treatment in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report
نویسندگان
1 Pediatric Growth and Development Research Center, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.. - Pediatric Growth and Development Research Center, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2 Firouzabadi Clinical Research Unit, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. - Firouzabadi Clinical Research Unit, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3 Department of Pediatrics, Rasool-e-Akram General Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran - Department of Pediatrics, Rasool-e-Akram General Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
doi
10.18502/ijpho.v16i2.21351چکیده
Thrombotic Thrombocytopenic purpura (TTP) is the thrombotic microangiopathy (TMA) caused by the severely reduced activity of the von Willebrand factor-cleaving protease ADAMTS13. The deficiency occurs in two main forms, acquired (antibody-mediated) and inherited. Plasma exchange is the mainstay of the disease management; however, Caplacizumab, glucocorticoids, rituximab, and other immunosuppressive drugs ...
